Investigating how ATRX mutations affect cell cycle regulation in pediatric high-grade glioma
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10873090
This study is looking at how certain changes in a gene called ATRX affect kids with a serious brain cancer called pediatric high-grade glioma, especially after they receive radiation treatment, to find new ways to help improve their care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10873090 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of ATRX mutations in pediatric high-grade glioma (pHGG), a severe form of brain cancer in children. The study aims to explore how these mutations disrupt normal cell cycle checkpoints, particularly after radiation treatment. By using advanced mouse models, researchers will investigate the epigenetic mechanisms behind this dysfunction and how it relates to other mutations commonly found in pHGG. The ultimate goal is to identify potential targeted therapies that could improve treatment outcomes for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with pediatric high-grade glioma, particularly those with ATRX mutations.
Not a fit: Patients without ATRX mutations or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that significantly improve survival rates for children with pediatric high-grade glioma.
How similar studies have performed: Previous research has shown promising results in understanding the role of ATRX mutations in cancer, but this specific approach to pediatric high-grade glioma is relatively novel.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOSCHMANN, CARL J — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: KOSCHMANN, CARL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.